MedTrace Logo

Phase I Human Analytics (HALO) Study

NCT05423860 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2022-10-14

No results posted yet for this study

Summary

Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders.

Additionally, the study aims to:

* Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis.
* Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms.
* Direct participants to relevant and applicable clinical trials.

Conditions

Interventions

OTHER

no interventions will be performed (observational)

Not applicable. (no interventions will be performed with this observational study

Sponsors & Collaborators

  • HALO Affiliate Sites

    collaborator UNKNOWN

  • HALO Diagnostics

    lead INDUSTRY

Principal Investigators

  • Christopher R. Hancock, MD · HALO Diagnostics

  • Erik W. Peterson, BS · HALO Diagnostics

Eligibility

Min Age
45 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2027-03-31
Completion
2037-03-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05423860 on ClinicalTrials.gov